Home LiteratureArticle Details
PMID: 9234793 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection.

Infection and immunity ·Vol. 65 ·No. 8 ·1997-08-00 ·Pages 3317-27

Hernandez-Pando R, Pavön L, Arriaga K, Orozco H, Madrid-Marina V, Rook G

Abstract

Mycobacteria are ubiquitous in the environment, but they are not part of the normal human microbial flora. It has been suggested that variable contact with mycobacteria can influence susceptibility to mycobacterial pathogens and the efficacy of subsequent Mycobacterium bovis BCG vaccination. To test this, mice were immunized with high or low doses of an environmental saprophyte, M. vaccae, that is intensely immunogenic as an autoclaved preparation. Two months later, they received an intratracheal challenge with M. tuberculosis H37Rv. Recipients of a low Th1-inducing dose (10(7) organisms) were partially protected and maintained a high ratio of interleukin 2 (IL-2)-positive to IL-4-positive cells in the perivascular, peribronchial, and granulomatous areas of the lung, whereas in unimmunized controls the IL-4-positive cells increased markedly between days 21 and 28. In contrast, recipients of the high dose (10(9) organisms), which primes Th2 as well as Th1 cytokine production, died more rapidly than unimmunized controls and showed massive pneumonia from day 7. The ratio of IL-2-positive to IL-4-positive cells in all compartments of the lung rapidly fell to 1 by day 14 for these animals. These events correlated with cytokine mRNA profiles and with increases in the local toxicity of tumor necrosis factor alpha (TNF-alpha), demonstrable only when a major Th2 component was present. These data indicate that cross-reactive epitopes present in an environmental saprophyte can evoke either protective responses or responses that increase susceptibility to M. tuberculosis. The latter are associated with the presence of a Th2 component and increased sensitivity to TNF-alpha.

MeSH Terms
Animals Environmental Microbiology Hypersensitivity, Delayed Immunization Immunohistochemistry Interleukin-2/analysis Interleukin-4/analysis Male Mice Mice, Inbred BALB C Mycobacterium/immunology Th2 Cells/physiology Tuberculosis/etiology,immunology,pathology Tumor Necrosis Factor-alpha/toxicity
Chemicals
Interleukin-2 Tumor Necrosis Factor-alpha Interleukin-4
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Hernandez-Pando R
Department of Pathology, Instituto Nacional de la Nutricion Salvador Zubiran, Mexico City, Mexico.
Pavön L
Arriaga K
Orozco H
Madrid-Marina V
Rook G
References (30)
30 references, click to expand
  1. Immune response to Mycobacterium bovis bacille Calmette Guérin infection in major histocompatibility complex class I- and II-deficient knock-out mice: contribution of CD4 and CD8 T cells to acquired resistance.
    Eur J Immunol. 1995 Feb;25(2):377-84 PMID: 7875199
  2. The role of TNF-alpha in T-cell-mediated inflammation depends on the Th1/Th2 cytokine balance.
    Immunology. 1994 Aug;82(4):591-5 PMID: 7835922
  3. Experimental approaches to mechanisms of protection and pathogenesis in M. tuberculosis infection.
    Immunobiology. 1994 Oct;191(4-5):526-36 PMID: 7713567
  4. Cytokine regulation of disease progression in leprosy and tuberculosis.
    Immunobiology. 1994 Oct;191(4-5):564-8 PMID: 7713571
  5. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells.
    Nature. 1995 May 11;375(6527):155-8 PMID: 7753173
  6. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.
    Immunity. 1995 Jun;2(6):561-72 PMID: 7540941
  7. T-cell cytokine responses in human infection with Mycobacterium tuberculosis.
    Infect Immun. 1995 Aug;63(8):3231-4 PMID: 7622255
  8. Variation in protection by BCG: implications of and for heterologous immunity.
    Lancet. 1995 Nov 18;346(8986):1339-45 PMID: 7475776
  9. Adrenal changes in murine pulmonary tuberculosis; a clue to pathogenesis?
    FEMS Immunol Med Microbiol. 1995 Sep;12(1):63-72 PMID: 8580904
  10. The pathogenesis of tuberculosis.
    Annu Rev Microbiol. 1996;50:259-84 PMID: 8905081
  11. Correlation between the kinetics of Th1, Th2 cells and pathology in a murine model of experimental pulmonary tuberculosis.
    Immunology. 1996 Sep;89(1):26-33 PMID: 8911136
  12. How environmental mycobacteria may predetermine the protective efficacy of BCG.
    Tubercle. 1981 Mar;62(1):55-62 PMID: 7268920
  13. Protective efficacy of BCG against leprosy in Northern Malawi.
    Lancet. 1986 Aug 30;2(8505):499-502 PMID: 2875247
  14. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection.
    Cell. 1989 Mar 10;56(5):731-40 PMID: 2647299
  15. Total and anti-mycobacterial IgE levels in serum from patients with tuberculosis and leprosy.
    Tubercle. 1989 Dec;70(4):273-9 PMID: 2516671
  16. Early delayed hypersensitivity responses in tuberculin skin tests after heavy occupational exposure to tuberculosis.
    J Clin Pathol. 1991 Nov;44(11):919-23 PMID: 1752982
  17. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
    J Exp Med. 1992 Apr 1;175(4):1111-22 PMID: 1552282
  18. A model for the investigation of factors influencing haemorrhagic necrosis mediated by tumour necrosis factor in tissue sites primed with mycobacterial antigen preparations.
    Clin Exp Immunol. 1992 Jun;88(3):537-42 PMID: 1606738
  19. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.
    Science. 1992 Jul 24;257(5069):539-42 PMID: 1636090
  20. TNF alpha-mediated tissue damage in mouse footpads primed with mycobacterial preparations.
    Res Immunol. 1992 Jul-Aug;143(6):601-10 PMID: 1360690
  21. A strategy to improve the efficacy of vaccination against tuberculosis and leprosy.
    Immunol Today. 1992 Sep;13(9):342-5 PMID: 1466750
  22. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
    J Exp Med. 1993 Jun 1;177(6):1675-80 PMID: 8496685
  23. Cytokine secretion by CD4 T lymphocytes acquired in response to Mycobacterium tuberculosis infection.
    J Immunol. 1993 Jul 1;151(1):518-25 PMID: 8100846
  24. Cytokine gene activation and modified responsiveness to interleukin-2 in the blood of tuberculosis patients.
    J Infect Dis. 1993 Oct;168(4):1056-9 PMID: 8376820
  25. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples.
    Biotechniques. 1993 Sep;15(3):532-4, 536-7 PMID: 7692896
  26. Complement receptor-mediated uptake and tumor necrosis factor-alpha-mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages.
    J Immunol. 1994 Jan 15;152(2):743-53 PMID: 8283049
  27. The role of CD8+ T cells in immunity to tuberculosis infection.
    Trends Microbiol. 1993 Jun;1(3):77-8 PMID: 8143120
  28. A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis.
    Immunology. 1994 Jun;82(2):244-8 PMID: 7927495
  29. Immune responsiveness and lymphokine production in patients with tuberculosis and healthy controls.
    Infect Immun. 1994 Dec;62(12):5673-8 PMID: 7960152
  30. Contribution of alpha/beta and gamma/delta T lymphocytes to immunity against Mycobacterium bovis bacillus Calmette Guérin: studies with T cell receptor-deficient mutant mice.
    Eur J Immunol. 1995 Mar;25(3):838-46 PMID: 7705416
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
1997-08-00
Pages
3317-27
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC175470
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]